NASDAQ:GOSS Gossamer Bio Q3 2026 Earnings Date & Estimates $10.74 +0.10 (+0.89%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. Gossamer Bio is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026TimeAfter Market Closes Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Gossamer Bio in Q3 2026Gossamer Bio is expected to post earnings of -$3.79 per share on revenue of $12.16 million. In the same quarter a year earlier Gossamer Bio reported -$16.80 per share on revenue of $13.29 million. Gossamer Bio last reported on May 15, 2026, posting -$16.00 per share and missing the -$13.60 consensus estimate. Gossamer Bio has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$3.79Expected Revenue$12.16 millionPrior-Year EPS-$16.80Prior-Year Revenue$13.29 millionExpected Revenue Growth-8.5%Recent Track RecordLast ReportedQ1 2026Last Quarter EPS-$16.00 (Missed by -$2.40)Last Quarter Revenue$16.96 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ1 2026 Earnings ReportQ4 2025 Earnings ReportQ3 2025 Earnings Report Gossamer Bio Q3 2026 Earnings FAQ When does Gossamer Bio report Q3 2026 earnings? Gossamer Bio (NASDAQ:GOSS) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Gossamer Bio's Q3 2026 earnings call? Gossamer Bio's Q3 2026 earnings conference call is scheduled for Friday, November 20, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Gossamer Bio? Analysts expect Gossamer Bio to post earnings of -$3.79 per share for Q3 2026. How much revenue is Gossamer Bio expected to report? The consensus revenue estimate for Gossamer Bio is $12.16 million for Q3 2026. Gossamer Bio Earnings HeadlinesGossamer Bio (GOSS) Set to Announce Quarterly Earnings on WednesdayNovember 2, 2026 | americanbankingnews.comGossamer Bio stockholders approve share issuance proposal under securities purchase agreement dated August 20, 2026October 28, 2026 | msn.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 10 at 1:00 AM | Behind the Markets (Ad)Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib RisksOctober 17, 2026 | finance.yahoo.comChardan Initiates Gossamer Bio at Buy With $160 Price TargetOctober 13, 2026 | marketscreener.comMGossamer Bio average analyst price target decreased by 40.76% to $80.05October 2, 2026 | msn.comSee More Gossamer Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gossamer Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gossamer Bio and other key companies, straight to your email. Email Address About Gossamer BioGossamer Bio (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders. Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company has also pursued additional investigational programs in immunology and inflammatory diseases. Gossamer Bio was founded in 2015 and is headquartered in San Diego, California. Its programs are advanced through clinical development and collaborations intended to support development and potential commercialization in the United States and international markets. The company’s leadership includes Chief Executive Officer Faheem Guirgis.View Gossamer Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
